Recommendations for the care of oral involvement in patients with systemic sclerosis

Arthritis Care and Research

Volumn 63, Issue 8, 2011, Pages 1126-1133

  Alantar, Alp ^a   Cabane, Jean ^b   Hachulla, Eric ^c   Princ, Guy ^a   Ginisty, Danielle ^a   Hassin, Michel ^a   Sorel, Marc ^d   Maman, Louis ^a   Pilat, Aurélie ^a   Mouthon, Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIV LILLE   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANETHOLE TRITHIONE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIVITAMIN K; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHLORHEXIDINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUORIDE; HYDROXYZINE; LIDOCAINE; MACROLIDE; METHOTREXATE; METRONIDAZOLE; PILOCARPINE; PREDNISONE; TRANEXAMIC ACID;

ADRENAL CORTEX INSUFFICIENCY; ANTIBIOTIC THERAPY; BLOOD TOXICITY; CANCER RISK; CARBON DIOXIDE LASER; CARIES PREVENTION; COMORBIDITY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DENTAL CARIES; DENTURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EDENTULOUSNESS; EMBOLISM PREVENTION; GASTROESOPHAGEAL REFLUX; GENERAL ANESTHESIA; GINGIVA BLEEDING; GINGIVA HYPERPLASIA; HUMAN; INFECTION PREVENTION; INFECTION RISK; JAW OSTEONECROSIS; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LUNG EMBOLISM; MENTAL DISEASE; MICROSTOMIA; MOUTH HYGIENE; MOUTH INFECTION; MOUTH MUCOSA; MOUTH ULCER; NEUTROPENIA; OSTEOLYSIS; OSTEOPOROSIS; PANORAMIC RADIOGRAPHY; PATIENT EDUCATION; PERIODONTITIS; PHARYNX CARCINOMA; PREVENTIVE DENTISTRY; PSYCHOPHARMACOTHERAPY; RAYNAUD PHENOMENON; REHABILITATION CARE; REVIEW; SIDE EFFECT; SJOEGREN SYNDROME; SMOKING CESSATION; SPLINT; STOMATITIS; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; THROMBOSIS PREVENTION; THRUSH; TONGUE CARCINOMA; TOOTH IMPLANTATION; TOOTH PROSTHESIS; TOOTH RADIOGRAPHY; TOOTH ROOT CANAL;

DENTAL CARE FOR CHRONICALLY ILL; HUMANS; MOUTH DISEASES; SCLERODERMA, SYSTEMIC; TOOTH DISEASES;

EID: 84860416347     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20480     Document Type: Review

References (77)

1. Tamby MC, Chanseaud Y, Guillevin L, Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003;2:152-7. (Pubitemid 37443852)
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50. (Pubitemid 38055920)
3. Servettaz A, Agard C, Tamby MC, Guilpain P, Guillevin L, Mouthon L. Systemic sclerosis: pathophysiology of a multifaceted disease. Presse Med 2006;35:1903-15. In French. (Pubitemid 44915261)
4. Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol 2010;22:133-8.
5. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
6. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573-6. (Pubitemid 32660630)
7. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
8. Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multiethnic county. Rheumatology (Oxford) 2004;43:1129-37. (Pubitemid 39232818)
9. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311-8.4
10. Mouthon L, Allanore Y, Cabane J, Hachulla E. Sclerodermie systemique. In: Guillevin L, Meyer O, Sibilia J, editors. Maladies et syndromes systemiques. Paris: Flammarion Medecine-Sciences; 2008. p. 410-70.
11. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
12. Scardina GA, Mazzullo M, Messina P. Early diagnosis of progressive systemic sclerosis: the role of oro-facial phenomena. Minerva Stomatol 2002;51:311-7. In Italian.
13. Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-item Short Form Health Survey. Arthritis Rheum 2007;57:94-102.
14. Tolle SL. Scleroderma: considerations for dental hygienists. Int J Dent Hyg 2008;6:77-83.
15. Scardina GA, Messina P. Systemic sclerosis: description and diagnostic role of the oral phenomena. Gen Dent 2004;52:42-7. (Pubitemid 39118619)
16. Mouthon L, Rannou F, Berezne A, Pagnoux C, Arene JP, Fois E, et al. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap in Systemic Sclerosis scale. Ann Rheum Dis 2007;66:1651-5. (Pubitemid 350205456)
17. Albilia JB, Lam DK, Blanas N, Clokie CM, Sandor GK. Small mouths... Big problems? A review of scleroderma and its oral health implications. J Can Dent Assoc 2007;73:831-6.
18. Prescription des antibiotiques en odontologie et stomatologie. 2001. URL: http://www.afssaps.fr/Infos-de-securite/Recommandations-de-bonne-pratique/ Prescription-desantibiotiques-en-odontologie-et-stomatologie-recommandationsde- bonne-pratique/(language)/fre-FR.
19. Recommandations sur la prise en charge bucco-dentaire des patients traites par bisphosphonates. 2007. URL: http://www.afssaps.fr/Infos-de-securite/ Lettres-aux-professionnels-de-sante/Recommandations-sur-la-prise-en-charge- bucco-dentaire-despatients-traites-par-bisphosphonates.
20. Haute Autorite de Sante, Protocole National de Diagnostic et de Soins-Sclerodermie systemique. 2008. URL: www.hassante.fr.
21. Woolf SH. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. Arch Intern Med 1992;152:946-52.
22. Avouac J, Sordet C, Depinay C, Ardizonne M, Vacher-Lavenu MC, Sibilia J, et al. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006;54:2243-9. (Pubitemid 44051082)
23. Shah AA, Wigley FM. Often forgotten manifestations of systemic sclerosis. Rheum Dis Clin North Am 2008;34:221-38. (Pubitemid 351343812)
24. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
25. Salliot C, Mouthon L, Ardizzone M, Sibilia J, Guillevin L, Gottenberg JE, et al. Sjogren's syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) 2007;46:321-6. (Pubitemid 46189795)
26. Avouac J, Airo P, Dieude P, Caramaschi P, Tiev K, Diot E, et al. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J Rheumatol 2010;37:608-14.
27. Wood RE, Lee P. Analysis of the oral manifestations of systemic sclerosis (scleroderma). Oral Surg Oral Med Oral Pathol 1988;65:172-8. (Pubitemid 18062291)
28. Scardina GA, Pizzigatti ME, Messina P. Periodontal microcirculatory abnormalities in patients with systemic sclerosis. J Periodontol 2005;76:1991-5. (Pubitemid 41748990)
29. Fischer DJ, Patton LL. Scleroderma: oral manifestations and treatment challenges. Spec Care Dentist 2000;20:240-4.
30. Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol 2005;32:637-41. (Pubitemid 40524694)
31. Haers PE, Sailer HF. Mandibular resorption due to systemic sclerosis: case report of surgical correction of a secondary open bite deformity. Int J Oral Maxillofac Surg 1995;24:261-7.
32. Rout PG, Hamburger J, Potts AJ. Orofacial radiological manifestations of systemic sclerosis. Dentomaxillofac Radiol 1996;25:193-6. (Pubitemid 126423881)
33. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesisdriven treatment strategies. Lancet 2006;367:1683-91. (Pubitemid 43728250)
34. Fischoff DK, Sirois D. Painful trigeminal neuropathy caused by severe mandibular resorption and nerve compression in a patient with systemic sclerosis: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:456-9.
35. Janssens X, Herman L, Mielants H, Verbruggen G, Veys EM. Disease manifestations of progressive systemic sclerosis: sensitivity and specificity. Clin Rheumatol 1987;6:532-8.
36. Spackman GK. Scleroderma: what the general dentist should know. Gen Dent 1999;47:576-9.
37. Leader DM. Scleroderma and dentistry: every dentist is a scleroderma specialist. J Mass Dent Soc 2007;56:16-9.
38. Ranque B, Authier FJ, Berezne A, Guillevin L, Mouthon L. Systemic sclerosis-associated myopathy. Ann NY Acad Sci 2007;1108:268-82. (Pubitemid 47528740)
39. Ranque B, Berezne A, Le-Guern V, Pagnoux C, Allanore Y, Launay D, et al. Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features. Scand J Rheumatol 2010;39:498-505.
40. Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008;67:110-6.
41. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-7. (Pubitemid 27160644)
42. Ranque B, Authier FJ, Le-Guern V, Pagnoux C, Berezne A, Allanore Y, et al. A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 2009;68:1474-7.
43. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
44. Thombs BD, Taillefer SS, Hudson M, Baron M. Depression in patients with systemic sclerosis: a systematic review of the evidence. Arthritis Rheum 2007;57:1089-97. (Pubitemid 47237338)
45. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2, 400 patient cases. J Cancer Res Clin Oncol 2010;136:1117-24.
46. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-36.
47. Pavicic MJ, van Winkelhoff AJ, Douque NH, Steures RW, de Graaff J. Microbiological and clinical effects of metronidazole and amoxicillin in Actinobacillus actinomycetemcomitans-associated periodontitis: a 2-year evaluation. J Clin Periodontol 1994;21:107-12.
48. Naylor WP, Manor RC. Fabrication of a flexible prosthesis for the edentulous scleroderma patient with microstomia. J Prosthet Dent 1983;50:536-8.
49. Naylor WP, Douglass CW, Mix E. The nonsurgical treatment of microstomia in scleroderma: a pilot study. Oral Surg Oral Med Oral Pathol 1984;57:508-11. (Pubitemid 14080669)
50. Al-Hadi LA. A simplified technique for prosthetic treatment of microstomia in a patient with scleroderma: a case report. Quintessence Int 1994;25:531-3.
51. Benetti R, Zupi A, Toffanin A. Prosthetic rehabilitation for a patient with microstomia: a clinical report. J Prosthet Dent 2004;92:322-7. (Pubitemid 39348980)
52. Sharon-Buller A, Sela M. Development of a device for removing a partial denture in a patient with scleroderma. Spec Care Dentist 2005;25:234-5. (Pubitemid 41527003)
53. Yenisey M, Kulunk T, Kurt S, Ural C. A prosthodontic management alternative for scleroderma patients. J Oral Rehabil 2005;32:696-700. (Pubitemid 41216047)
54. Kam AY, Chung WC, Luk WK. Oral rehabilitation of a patient with scleroderma associated with systematic lupus erythematosus: a case report. Spec Care Dentist 2006;26:121-3. (Pubitemid 44023277)
55. Samet N, Tau S, Findler M, Susarla SM. Flexible, removable partial denture for a patient with systemic sclerosis (scleroderma) and microstomia: a clinical report and a three-year follow-up. Gen Dent 2007;55:548-51.
56. Dikbas I, Koksal T, Kazazoglu E. Fabricating sectionalcollapsible complete dentures for an edentulous patient with microstomia induced by scleroderma. Quintessence Int 2007;38:15-22. (Pubitemid 44948164)
57. Colvenkar SS. Sectional impression tray and sectional denture for a microstomia patient. J Prosthodont 2010;19:161-5.
58. Oczakir C, Balmer S, Mericske-Stern R. Implant-prosthodontic treatment for special care patients: a case series study. Int J Prosthodont 2005;18:383-9. (Pubitemid 41433749)
59. Raviv E, Harel-Raviv M, Shatz P, Gornitsky M. Implantsupported overdenture rehabilitation and progressive systemic sclerosis. Int J Prosthodont 1996;9:440-4. (Pubitemid 126700478)
60. Patel K, Welfare R, Coonar HS. The provision of dental implants and a fixed prosthesis in the treatment of a patient with scleroderma: a clinical report. J Prosthet Dent 1998;79:611-2.
61. Hseu SS, Sung CS, Mao CC, Tsai SK, Lee TY. Anesthetic management in a parturient with progressive systemic sclerosis during cesarean section: a case report. Acta Anaesthesiol Sin 1997;35:161-6.
62. Veiga G, Sanchez JJ, Garcia E, Candia C. Anesthetic considerations in scleroderma [letter]. Rev Esp Anestesiol Reanim 2007;54:508-9. In Spanish.
63. Coral-Alvarado P, Rojas-Villarraga A, Latorre MC, Mantilla RD, Restrepo JF, Pardo AL, et al. Risk factors associated with pulmonary arterial hypertension in Colombian patients with systemic sclerosis: review of the literature. J Rheumatol 2008;35:244-50. (Pubitemid 351281145)
64. Poole JL. Musculoskeletal rehabilitation in the person with scleroderma. Curr Opin Rheumatol 2010;22:205-12.
65. Vincent C, Agard C, Barbarot S, N'Guyen JM, Planchon B, Durant C, et al. Orofacial manifestations of systemic sclerosis: a study of 30 consecutive patients. Rev Stomatol Chir Maxillofac 2010;111:128-34. In French.
66. Patel M, Shackleton JA, Coogan MM, Galpin J. Antifungal effect of mouth rinses on oral Candida counts and salivary flow in treatment-naive HIV-infected patients. AIDS Patient Care STDS 2008;22:613-8.
67. Quirynen M, Bollen CM, Vandekerckhove BN, Dekeyser C, Papaioannou W, Eyssen H. Full-vs. partial-mouth disinfection in the treatment of periodontal infections: short-term clinical and microbiological observations. J Dent Res 1995;74:1459-67.
68. Poole J, Conte C, Brewer C, Good CC, Perella D, Rossie KM, et al. Oral hygiene in scleroderma: the effectiveness of a multidisciplinary intervention program. Disabil Rehabil 2010;32:379-84.
69. Cabane J. Living with scleroderma. Rev Prat 2002;52:1918-22. In French.
70. Pizzo G, Scardina GA, Messina P. Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma. Clin Oral Investig 2003;7:175-8.
71. Maddali Bongi S, Del Rosso A, Galluccio F, Tai G, Sigismondi F, Passalacqua M, et al. Efficacy of a tailored rehabilitation program for systemic sclerosis. Clin Exp Rheumatol 2009;27 Suppl: 44-50.
72. Maloney GE, Mehta N, Forgione AG, Zawawi KH, Al-Badawi EA, Driscoll SE. Effect of a passive jaw motion device on pain and range of motion in TMD patients not responding to flat plane intraoral appliances. Cranio 2002;20:55-66.
73. 2 pulse des plis radies peribuccaux dans la sclerodermie. Ann Dermatol Venereol 2008;135 Suppl: 94.
74. Marton K. Oral symptoms of immunologic disorders. Part I. Systemic autoimmune diseases. Fogorv Sz 2003;96:9-15. In Hungarian.
75. Tajani AH, Nesbitt SD. Gingival hyperplasia in a patient with hypertension. J Clin Hypertens (Greenwich) 2008;10:863-5.
76. Abitbol TE, Rosenfeld-Abitbol M. Surgical treatment of nifedipine-induced gingival hyperplasia: a case report. NY State Dent J 1996;62:34-7.
77. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.